赫赛汀和9-顺式视黄酸联合用药对裸鼠转染HER2基因乳腺癌效应的研究  

THE SYNERGISTIC EFFECTS OF HERCEPTIN AND 9-CIS-RETINOIC ACID ON HER2/NEU POSITIVE BREAST CANCER CELLS IN VIVO

作　　者：郎海滨[1] 糜漫天[1] 

机构地区：[1]第三军医大学营养与食品卫生学教研室暨重康市营养与食品安全重点实验室,重庆400038

出　　处：《营养学报》2008年第1期70-73,共4页Acta Nutrimenta Sinica

基　　金：国家自然科学基金(No.30300285)

摘　　要：目的探讨赫赛汀(Herceptin,HER)和9-顺式视黄酸(9-cis-RA)单独和联合用药对HER2阳性乳腺癌细胞裸鼠移植瘤的协同抑制效应及其相应机制。方法将处于对数生长期的MCF-7HER2细胞皮下注射到Balb/c裸鼠体内,4w后,HER和9-cis-RA分别单独和联合处理裸鼠移植瘤模型3w,测量各组移植瘤的体积大小并计算出相应的q值。同时观察移植瘤的组织结构,并利用免疫组化法检测移植瘤细胞Ki-67蛋白的表达变化,以检测移植瘤细胞的增殖活性。结果HER和9-cis-RA联合作用组较对照和单独作用组能显著减小HER2阳性乳腺癌细胞裸鼠移植瘤的体积并有效改变其组织病理结构,同时还能在体内显著抑制HER2阳性乳腺癌细胞的增殖活性。结论联合应用HER和9-cis-RA可在体内有效协同发挥抑制HER2阳性乳腺癌细胞的作用。Objective To observe the synergistic effects of Herceptin （HER） and 9-cis-retinoic acid （9-cis-RA） on HER2/neu positive breast cancer cells in vivo. Method MCF-7 breast cancer cells transfected with exogenous HER2 gene were inoculated into athymic nude mice. Four weeks after tumor inoculation, mice bearing a tumor of 200 mm3 in volume approximately were selected to be treated with HER and/or 9-cis-RA（SC） for 20d. After that tumor volume was precisely measured, concurrently the HE staining and Ki-67 immunohistochemical （IHC） assay were performed to detect the anti-proliferative effect of HER in combination with 9-cis-RA in vivo. Results After 3 w of treatment, HER and 9-cis-RA synergistically decreased the tumor volume as compared with control group. IHC results showed that Ki-67 expression was significantly inhibited by co-treatment of HER and 9-cis-RA, which means the arrest of cell cycle progression. Conclusion Herceptin and 9-cis-RA could synergistically inhibit the proliferation of HER2 positive breast cancer cells in vivo.[ACTA NUTRIMENTA SINICA, 2008, 30 （1）：70-73]

关 键 词：赫赛汀 9-顺式视黄酸 乳腺癌 HER2 裸鼠 

分 类 号：R737.9[医药卫生—肿瘤]